Livedo Reticularis (Primär, Investigativ)

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?

Not FDA-cleared for primary livedo reticularis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.

Welche Evidenz existiert?

Tier C (investigational). There are no published controlled trials. Primary (idiopathic) livedo reticularis is generally benign and reversible with cold avoidance; it is associated with low ambient temperature, vasospasm, and occasionally medications. Secondary livedo can reflect serious systemic disease (antiphospholipid syndrome, vasculitis, cholesterol embolism, cryoglobulinemia) - workup must distinguish before any intervention. Evidence-based management of primary livedo is reassurance, smoking cessation, cold avoidance, treatment of any contributing medication, and (if symptomatic) low-dose aspirin or pentoxifylline.

Hauptrisiken

• Bleeding from each bite site for 6 to 24 hours after detachment
• Bruising on already-mottled skin for 5 to 10 days
• Local skin or, rarely, Aeromonas hydrophila infection
• Allergic reaction to leech saliva (uncommon)
• Triggering an ulcer in livedo-affected skin (livedoid vasculopathy ulcers heal poorly)
• Worsening cold sensitivity from local vasoconstrictor response
• Delay of workup for serious secondary causes (antiphospholipid syndrome, vasculitis)

Wer dies nicht in Betracht ziehen sollte

• Patients with secondary livedo from systemic disease (workup needed first)
• Patients with livedoid vasculopathy (ulcerative subtype - bleeding and ulcer risk)
• Patients with antiphospholipid syndrome on anticoagulation (which is an absolute contraindication anyway)
• Patients with active vasculitis, cholesterol embolism, or cryoglobulinemia
• Patients on anticoagulants, with hemophilia, or with severe anemia
• Patients with critical limb ischemia (ABI under 0.4)
• Patients with active dermatitis or broken skin over the livedo-affected region

Was Sie Ihren Kliniker fragen sollten

• Has secondary livedo been ruled out (antiphospholipid screen, ANA, ANCA, cryoglobulins, lipid panel)?
• Is this primary (idiopathic) livedo, livedoid vasculopathy, or livedo racemosa?
• Have I addressed cold avoidance, smoking, and any vasoconstrictor medications?
• Is the livedo causing functional impairment or any symptom beyond appearance?
• What is the rationale for any intervention given primary livedo is generally benign?
• Where exactly will leeches be placed, and what is the plan if ulceration occurs?
• What is the Aeromonas-prevention protocol?

Wann dringende medizinische Versorgung suchen

• New ulceration in livedo-affected skin
• Sudden coolness, pallor, or pulselessness of a limb (possible arterial occlusion)
• Sudden severe limb pain with mottling (possible cholesterol embolism)
• Systemic symptoms - fever, weight loss, joint pain, rash, kidney symptoms (possible vasculitis)
• Stroke symptoms - sudden weakness, speech difficulty, vision change (possible antiphospholipid syndrome)
• Bleeding from a bite site lasting more than 24 hours
• Hives, facial or throat swelling, or breathing difficulty